Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

Department of Discovery Biology, CGI Pharmaceuticals, Branford, Connecticut, USA.
Nature Chemical Biology (Impact Factor: 12.95). 01/2011; 7(1):41-50. DOI: 10.1038/nchembio.481
Source: PubMed

ABSTRACT Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and molecular mechanisms by which Btk mediates inflammation are poorly understood. Here we describe the discovery of CGI1746, a small-molecule Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation. CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation. Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms. CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis. In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 production. Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease. These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Amides are prevalent in organic synthesis. Developing an efficient synthesis that avoids expensive oxidants and heating is highly desirable. Here the oxidative amidation of aromatic aldehydes is reported using an inexpensive metal-free visible light photocatalyst, phenazine ethosulfate, at low catalytic loading (1-2 mol %). The reaction proceeds at ambient temperature and uses air as the sole oxidant. The operationally easy procedure provides an economical, green, and mild alternative for the formation of amide bonds.
    Organic Letters 10/2014; · 6.32 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bregs (regulatory B cells) are important in immune regulation. The regulatory factors on Breg functions are less understood. IGF2 (Insulin-like growth factor 2) is capable of inducing hematopoietic stem cell differentiation. This study aims to investigate the role of IGF2 in the development of Bregs and enhancement of Breg's function. In this study, the expression of IGF1R and IGF2R in OVAsBCs (ovalbumin (OVA)-specific B cells) was assessed by real time RT-PCR and Western blotting. The releasing of interleukin (IL)-10 from OVAsBCs and OVAsBC proliferation were assessed by enzyme-linked immunoassay and proliferation assay. The role of IGF2 in enhancing OVAsBCs' function was tested with an intestinal allergic inflammation mouse model. The results showed that OVAsBCs expressed high levels of IGF2R (IGF2 receptor). Exposure to both IGF2 and specific Ag (antigen), OVA, markedly enhanced the expression of IL-10 in OVAsBCs, as well as enhanced the IL-10+ OVAsBC proliferation. The concurrent exposure to IGF2 and specific Ag markedly induced the IL-10 promoter DNA demethylation via activating the STAT5 pathway. IGF2 also enhanced the OVAsBC proliferation in vivo and enhanced the effect of Ag-specific immunotherapy on inhibiting allergic inflammation in the intestine. We conclude that OVAsBCs express high levels of IGF2R. IGF2 increases the expression of IL-10 in OVAsBCs, enhances OVAsBC proliferation and the inhibitory effect on allergic inflammation.
    Journal of Biological Chemistry 05/2014; · 4.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bruton's tyrosine kinase (Btk) is an attractive drug target for treating several B-cell lineage cancers. Ibrutinib is a first-in-class covalent irreversible Btk inhibitor and has demonstrated impressive effects in multiple clinical trials. Herein, we present a series of novel 2,5-diaminopyrimidine covalent irreversible inhibitors of Btk. Compared with ibrutinib, these inhibitors exhibited a different selectivity profile for the analyzed kinases as well as a dual-action mode of inhibition of both Btk activation and catalytic activity, which counteracts a negative regulation loop for Btk. Two compounds from this series, 31 and 38, showed potent antiproliferative activities toward multiple B-cell lymphoma cell lines, including germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) cells. In addition, compound 31 significantly prevented tumor growth in a mouse xenograft model.
    Journal of Medicinal Chemistry 06/2014; · 5.48 Impact Factor